返回
AC Immune SA（ACIU）价格
ACIU 股价走势图
ACIU 收益
AC Immune SA
$3.55
1.13%
$0.04
截至今日：Jan 20, 11:42:22 GMT-5
关键数据
前收盘价
$3.51
开盘价
$3.53
当日区间
$3.4 - $3.59
52周范围
$1.43 - $4
交易量
105.9K
平均成交量
713.5K
每股收益（TTM）
-0.72
股息收益率
--
市值
$356.4M
什么是 ACIU？
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.